As of Friday close, Bionano Genomics Inc.’s (NASDAQ:BNGO) stock was down -$0.06, moving down -1.97 percent to $2.98. The average number of shares traded per day over the past five days has been 1,320,100 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.01 fall in that time frame. In the last twenty days, the average volume was 1,249,703, while in the previous 50 days, it was 1,171,294.
Since last month, BNGO stock retreated -49.08%. Shares of the company fell to $2.98 on 08/18/23, the lowest level in the past month. A 52-week high of $32.90 was reached on 02/02/23 after having rallying from a 52-week low of $3.01. Since the beginning of this year, BNGO’s stock price has dropped by -79.59% or -$11.62, and marked a new high 8 times. However, the stock has declined by -90.94% since its 52-week high.
BNGO stock investors should be aware that Bionano Genomics Inc. (BNGO) stock had its last reported insider trading activity 67 days ago on Jun 13. Mamuszka Hannah, the Director of the company, purchased of 65,789 shares for $0.76 on Jun 13. It resulted in a $50,000 investment by the insider. Holmlin R. Erik added 15,000 shares at an average price of $0.64 on May 16. The insider now owns 806,474 shares following the transaction. On May 12, Chief Financial Officer Stewart Christopher P. bought 50,000 shares at $0.67 apiece. The transaction was valued at $33,415.
Valuation Metrics
The stock’s beta is 2.26. Besides these, the trailing price-to-sales (P/S) ratio of 3.10, the price-to-book (PB) ratio of 0.44.
Financial Health
In the three months ended June 29, Bionano Genomics Inc.’s quick ratio stood at 2.70, while its current ratio was 3.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.02, and the total debt-to-equity ratio was 0.02. On the profitability front, the trailing twelve-month gross margin is 24.20% percent. Based on annual data, BNGO earned $5.95 million in gross profit and brought in $27.8 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -52.70%. Return on equity (ROE) for the past 12 months was -60.00%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BNGO’s revenue rose 22.98% to $7.42 million during the quarter, while net income inched up to $8.66 million. While analysts expected Bionano Genomics Inc. to report -$1.03 quarterly earnings, the actual figure was -$1.24 per share, beating the consensus estimate by -20.40%. During the quarter, the company generated -$36.03 million in EBITDA. The liabilities of Bionano Genomics Inc. were 56.62 million at the end of its most recent quarter ended June 29, and its total debt was $10.66 million. The value of shareholders’ equity is $35.35 million.
Technical Picture
This quick technical analysis looks at Bionano Genomics Inc.’s (BNGO) price momentum. With a historical volatility rate of 76.04%, the RSI 9-day stood at 13.11% on 18 August.
With respect to its five-day moving average, the current Bionano Genomics Inc. price is down by -25.31% percent or -$1.01. At present, BNGO shares trade -50.07% below its 20-day simple moving average and -72.91% percent below its 100-day simple moving average. However, the stock is currently trading approximately -60.48% below its SMA50 and -87.26% below its SMA200.
Stochastic coefficient K was 2.29% and Stochastic coefficient D was 3.60%, while ATR was 0.36. Given the Stochastic reading of 0.00% for the 14-day period, the RSI (14) reading has been calculated as 18.54%. As of today, the MACD Oscillator reading stands at -0.53, while the 14-day reading stands at -1.20.
Analyst Ratings
Scotiabank launched its rating on Bionano Genomics Inc. (NASDAQ: BNGO) to a Sector outperform in a note to investors on January 05, 2023. Bionano Genomics Inc. (BNGO) has been rated Buy by analysts. According to 0 brokerage firms, BNGO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Bionano Genomics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $17.50, the current consensus forecast for the stock is $9.00 – $32.00. Based on these forecasts, analysts predict Bionano Genomics Inc. (BNGO) will achieve an average price target of $17.70.
